Tech Company Financing Transactions
Core Biogenesis Funding Round
On 7/29/2022, Core Biogenesis raised $10.5 million in Series A funding from Xange, Blue Horizon Ventures and Thia Ventures.
Transaction Overview
Company Name
Announced On
7/29/2022
Transaction Type
Venture Equity
Amount
$10,500,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to build out an industrial scale facility dedicated to producing growth factors and cytokines for the cell therapy market and cellular agriculture industry, and to hire additional scientific and technical staff to support the expansion.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Station F, 5 Parvis Alan Turing,
Paris, 75013
FRANCE
Paris, 75013
FRANCE
Phone
Undisclosed
Website
Email Address
Overview
Core Biogenesis uses plants as biofactories to scale the production of high-value bioproducts. Our Ultra-scalable bioproduction as a service (UBaaS) platform accelerates mass production and increases yields, while driving down costs. By unlocking a new paradigm in recombinant molecule production, we are helping build a more sustainable future.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alexandre Reeber
Chief Scientific Officer
Chouaib Meziadi
Co-Founder
Maurice Moloney
VP - Operations
Clemence Bellanger
Browse more venture capital transactions:
Prev: 7/29/2022: Renting Finders venture capital transaction
Next: 7/29/2022: Linkup venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs